NASDAQ: XRAYDentsply Sirona Inc Stock
$11.65+0.56 (+5.05%)
Updated Jul 2, 2026
XRAY Price
$11.65
Fair Value Price
$18.39
Market Cap
$2.33B
52 Week Low
$9.41
52 Week High
$17.09
P/E
-3.71x
P/B
1.77x
P/S
0.63x
PEG
N/A
Dividend Yield
2.75%
Revenue
$3.68B
Earnings
-$628.00M
Gross Margin
48.9%
Operating Margin
-13.04%
Profit Margin
-17.1%
Debt to Equity
2.97
Operating Cash Flow
$268M
Beta
0.93
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
XRAY Overview
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XRAY's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical
Industry Rating
B
XRAY
Ranked#24 of 41
Ranked#24 of 41
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.16 | A | |
| $24.84 | A | |
| $17.16 | B |
Be the first to know about important XRAY news, forecast changes, insider trades & much more!
XRAY News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XRAY scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XRAY ($11.65) is undervalued by 36.64% relative to our estimate of its Fair Value price of $18.39 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
XRAY ($11.65) is significantly undervalued by 36.64% relative to our estimate of its Fair Value price of $18.39 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
XRAY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more XRAY due diligence checks available for Premium users.
Valuation
XRAY fair value
Fair Value of XRAY stock based on Discounted Cash Flow (DCF)
Price
$11.65
Fair Value
$18.39
Undervalued by
36.64%
XRAY ($11.65) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XRAY ($11.65) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XRAY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
XRAY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.71x
Industry
45.19x
Market
8.54x
XRAY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.77x
Industry
3.43x
XRAY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XRAY's financial health
Profit margin
Revenue
$880.0M
Net Income
-$10.0M
Profit Margin
-1.1%
XRAY's Earnings (EBIT) of -$480.00M... subscribe to Premium to read more.
Interest Coverage Financials
XRAY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.2B
Liabilities
$3.9B
Debt to equity
2.97
XRAY's short-term assets ($1.85B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XRAY's long-term liabilities ($2.70B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XRAY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
XRAY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$40.0M
Investing
-$53.0M
Financing
-$119.0M
XRAY's operating cash flow ($268.00M)... subscribe to Premium to read more.
Debt Coverage Financials
XRAY vs Medical Stocks
Dentsply Sirona Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.